Drug Profile

Niraparib - Janssen/Merck/GSK

Alternative Names: GSK-3985771; JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula; ZL 2306

Latest Information Update: 19 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Merck & Co
Developer Bayer; Dana-Farber Cancer Institute; Emory University; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Georgetown University; GSK; Hunan Cancer Hospital; Janssen; Katholieke Universiteit Leuven; Massachusetts General Hospital; Medica Scientia Innovation Research; Merck & Co; Myriad Genetics; NeoGenomics; Novocure Limited; OncoQuest; Resolution Bioscience; Sarcoma Alliance for Research through Collaboration; Takeda; Tempus; TESARO; The Ivy Brain Tumor Center; Thomas Jefferson University; University Health Network; University of Florida; University of Kansas Medical Center; University of Oklahoma; University of Pennsylvania; University of Texas M. D. Anderson Cancer Center; University of Turin; University of Utah; ZAI Lab
Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer
New Molecular Entity Yes

Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Phase III Breast cancer; Glioblastoma; HER2 negative breast cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
Phase II Cervical cancer; Cholangiocarcinoma; CNS cancer; Endometrial cancer; Mesothelioma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
No development reported Ewing's sarcoma; Gastric cancer; Haematological malignancies

23 Mar 2026 GSK completed phase III trial in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) in USA, Belgium, Bulgaria, Greece, Ireland, South Korea, Netherlands, Norway, Poland, Sweden, Turkey, Australia, Netherlands, Norway, Sweden, Argentina, Brazil, Chile, China, Colombia, Denmark, France, Germany, Hungary, Italy, Japan, Mexico, Peru, Romania, Russia, Spain, Switzerland, United Kingdom (PO) (NCT04475939) (EudraCT2020-002202-20)
28 Feb 2026 Dana-Farber Cancer Institute completes a phase-II trial in Pancreatic cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT03601923)
09 Dec 2025 Updated adverse events and efficacy data from a phase-II trial in Breast cancer (Neoadjuvant therapy, Combination therapy) presented at the 48^th Annual San Antonio Breast Cancer Symposium (SABCS-2025 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com